Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
Stocks · News reference
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, visit analyst ratings page. Consider buying AKTS stock? Analysts weigh in.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37
BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs
Bank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carries the widest gap to target.
Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate
Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 98.03 percent increase over losses of $(22.39) per share from
Securities Fraud Investigation Into Better Home & Finance Holding Company (BETR) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is investigating Better Home & Finance Holding Company for potential federal securities law violations. The company's stock fell 28.5% on May 7, 2026, after missing its $1.0 billion monthly funded loan volume target, and dropped another 36.56% on August 4, 2026, following the abrupt CEO change from founder Vishal Garg to interim CEO Daniel Lewis.
Garg Group Confirms That Better Stockholders Can Vote Their Shares in the Garg Group’s Consent Solicitation with Confidence and Certainty
Vishal Garg, founder and former CEO of Better Home & Finance, confirmed that stockholders can safely vote in his consent solicitation to remove five board directors. Federal courts rejected Better's attempt to halt the solicitation, and Delaware courts confirmed that voting will not trigger the company's poison pill provision. The Garg Group has filed definitive consent solicitation materials with the SEC.